Optimization of Eliglustat-Based Glucosylceramide Synthase Inhibitors as Substrate Reduction Therapy for Gaucher Disease Type 3.
Wilson MW, Shu L, Hinkovska-Galcheva V, Jin Y, Rajeswaran W, Abe A, Zhao T, Luo R, Wang L, Wen B, Liou B, Fannin V, Sun D, Sun Y, Shayman JA, Larsen SD.
Wilson MW, et al. Among authors: fannin v.
ACS Chem Neurosci. 2020 Oct 21;11(20):3464-3473. doi: 10.1021/acschemneuro.0c00558. Epub 2020 Oct 9.
ACS Chem Neurosci. 2020.
PMID: 33035424
Free PMC article.